ESR1 and breast carcinoma: It also has been shown that ALDH1+ breast cancers are characterized by negative estrogen receptor (ER−), positive human epidermal growth factor receptor type 2 (EGFRII+), high expression of the proliferation marker Ki-67, and significantly lower pathologic complete response rates to neoadjuvant chemotherapy compared to ALDH− breast cancers.